BackgroundExposure to variable weak magnetic fields, reported to have shown beneficial effects on several neurological illnesses. However, existing therapies are costly, complex, and lack subject ease for frequent follow ups. In the current study, the novel BeCurie™ (Evolv28) wearable neck device that emits variable complex weak magnetic fields (VCMF’s) is evaluated for its positive impact on subjects with perceived stress and anxiety.MethodsEighteen participants were enrolled in this study. The primary outcomes of the study were to assess the improvements in perceived stress and anxiety symptoms in the BeCurie™ treated group. Stress and anxiety scores were assessed using DASS-21, HAM-A, and PSS. Quality of life was assessed using the MQoL-R questionnaire. Serum Cortisol and complete blood profile were assessed to understand the safety profile of BeCurie™ treatment.ResultsParticipants in the BeCurie™ group showed a significant reduction in stress and anxiety scores compared to the placebo group on Day 30. Furthermore, open label study assessments on Days 60 and 90 revealed improvements in self-reported stress and anxiety scores, significant time dependent improvements in all major domains of quality of life, including physical, psychological, existential, and support-based aspects of life. No adverse events were reported during the study. Comprehensive blood profile assessment showed no significant changes in either the placebo or BeCurie™ groups.ConclusionsThe findings indicate that VCMF’s emitted by the BeCurie™ device can be a supporting non-invasive alternative therapy for managing stress and anxiety. Nonetheless, the limitations of the study, including the small sample size and the lack of a follow-up assessment beyond 90 days, suggest that further investigations are needed to establish the long-term efficacy of BeCurie™ in managing stress and anxiety symptoms.